Breakthrough T1D awarded Greenstone Biosciences a $1.2 million, three-year grant to study biologic variation in type 1 diabetes using stem cell-derived 3D pancreatic islet organoids. Greenstone will generate induced pluripotent stem cells (iPSCs) from 20 diverse T1D participants, differentiate them into organoid models, and apply single-cell RNA sequencing, chromatin accessibility mapping, proteomics, and metabolomics to characterize beta-cell responses. The program aims to identify targets tied to differential beta-cell behavior under metabolic stress and to support biomarker discovery and improved therapeutic precision. Greenstone also plans to bank iPSC lines and share summary-level data publicly. The funding highlights continued momentum for translational cell platforms that connect patient-derived biology to mechanistic discovery in T1D.